Gvh-267 ((top))

GVH-267 selectively binds to and inhibits VEGFR-2 and VEGFR-3, thereby blocking the downstream signaling pathways involved in angiogenesis. By inhibiting these receptors, GVH-267 disrupts the formation of new blood vessels that feed the growth of cancer cells, ultimately leading to antitumor effects.

GVH-267, a newly synthesized compound, has shown promising therapeutic potential in various preclinical studies. This paper provides an overview of GVH-267's chemical structure, mechanism of action, and its applications in treating various diseases. Our research suggests that GVH-267 exhibits potent activity against multiple targets, making it a valuable candidate for further development. GVH-267

She put the vial back in the freezer.